As of May 30, 2026, Aurinia Pharmaceuticals's top three insider holders are Peter Greenleaf (Chief Executive Officer, 1.84Mn shares), Matthew Maxwell Donley (Chief Operating Officer, 680.30K shares), Joseph M Miller (Chief Financial Officer, 576.42K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| George M Jr Milne | - | 78,733 | 0 | 23 May, 2023 |
| Peter Greenleaf | Chief Executive Officer | 1,840,379 | 0 | 03 Mar, 2026 |
| Craig A Johnson | - | 14,592 | 0 | 24 Nov, 2025 |
| Matthew Maxwell Donley | Chief Operating Officer | 680,299 | 0 | 03 Mar, 2026 |
| Karen L. Smith | - | 24,807 | 0 | 25 Nov, 2024 |
| Joseph M Miller | Chief Financial Officer | 576,421 | 0 | 03 Mar, 2026 |
| Volker Knappertz | Evp, Research And Development | 319,128 | 0 | 29 Feb, 2024 |
| Jill Leversage | - | 25,053 | 0 | 25 Nov, 2024 |
| Daniel Billen | - | 28,141 | 0 | 22 May, 2024 |
| Massimilano Colao | Chief Commercial Officer | 13,495 | 0 | 04 Mar, 2022 |
| Michael Robert Martin | Chief Business Officer | 259,162 | 0 | 06 Mar, 2023 |
| Robert Bindert Huizinga | Evp Of Research | 69,379 | 0 | 04 Mar, 2022 |
| Neil Solomons | Chief Medical Officer | 90,953 | 0 | 04 Mar, 2022 |
| Stephen P. Robertson | Evp, General Counsel | 505,861 | 0 | 03 Mar, 2026 |
| David R.W. Jayne | - | 56,499 | 0 | 25 Nov, 2024 |
| R. Hector Mackay-Dunn | - | 18,595 | 0 | 22 May, 2024 |
| Brinda Balakrishnan | - | 17,523 | 0 | 22 May, 2024 |
| Scott Michael Habig | Chief Commercial Officer | 456,338 | 0 | 07 Aug, 2024 |
| Greg Keenan | Svp, Chief Medical Officer | 154,449 | 0 | 10 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 06 Mar, 2026 | Greg Keenan | Common Stock | D | 8,069 | $14.32 | 154,449 | D | F |
| 06 Mar, 2026 | Greg Keenan | Common Stock | D | 8,069 | $14.32 | 154,449 | D | F |
| 27 Feb, 2026 | Joseph M Miller | Common Stock | A | 57,229 | $0.00 | 613,932 | D | A |
| 27 Feb, 2026 | Stephen P. Robertson | Common Stock | A | 59,090 | $0.00 | 542,386 | D | A |
| 27 Feb, 2026 | Stephen P. Robertson | Common Stock | A | 59,090 | $0.00 | 542,386 | D | A |
| 27 Feb, 2026 | Greg Keenan | Common Stock | A | 40,586 | $0.00 | 162,518 | D | A |
| 27 Feb, 2026 | Joseph M Miller | Common Stock | A | 57,229 | $0.00 | 613,932 | D | A |
| 27 Feb, 2026 | Matthew Maxwell Donley | Common Stock | A | 58,160 | $0.00 | 721,060 | D | A |
| 27 Feb, 2026 | Greg Keenan | Common Stock | A | 40,586 | $0.00 | 162,518 | D | A |
| 27 Feb, 2026 | Peter Greenleaf | Common Stock | A | 196,403 | $0.00 | 1,941,269 | D | A |
| 02 Mar, 2026 | Joseph M Miller | Common Stock | D | 37,511 | $14.21 | 576,421 | D | F |
| 27 Feb, 2026 | Greg Keenan | Employee Stock Option (right to buy) | A | 67,870 | $0.00 | 67,870 | D | A |
| 27 Feb, 2026 | Greg Keenan | Employee Stock Option (right to buy) | A | 67,870 | $0.00 | 67,870 | D | A |
| 02 Mar, 2026 | Stephen P. Robertson | Common Stock | D | 36,525 | $14.21 | 505,861 | D | F |
| 02 Mar, 2026 | Matthew Maxwell Donley | Common Stock | D | 40,761 | $14.21 | 680,299 | D | F |
| 02 Mar, 2026 | Stephen P. Robertson | Common Stock | D | 36,525 | $14.21 | 505,861 | D | F |
| 02 Mar, 2026 | Joseph M Miller | Common Stock | D | 37,511 | $14.21 | 576,421 | D | F |
| 02 Mar, 2026 | Peter Greenleaf | Common Stock | D | 100,890 | $14.21 | 1,840,379 | D | F |
| 27 Feb, 2026 | Matthew Maxwell Donley | Employee Stock Option (right to buy) | A | 97,256 | $0.00 | 97,256 | D | A |
| 27 Feb, 2026 | Peter Greenleaf | Employee Stock Option (right to buy) | A | 328,424 | $0.00 | 328,424 | D | A |